NCT02939846View on ClinicalTrials.gov

Pharmacokinetics of Single and Repeat Oral Doses of Trametinib in Chinese Subjects With Solid Tumours

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 31, 2017

Primary Completion Date

August 31, 2018

Study Completion Date

December 31, 2018

Conditions
Cancer
Interventions
DRUG

Trametinib

Trametinib study will be provided as 0.5 mg and 2.0 mg tablets. Each tablet will contain 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02939846 - Pharmacokinetics of Single and Repeat Oral Doses of Trametinib in Chinese Subjects With Solid Tumours | Biotech Hunter | Biotech Hunter